Kim FRISCH    SITE

Kim Frisch (PhD, MSc) is radiochemist and senior scientist at the Department of Nuclear Medicine and PET Centre at Aarhus University Hospital in Denmark. His obtained his degrees at the Department of Chemistry, Aarhus University: Master in organic electrochemistry and PhD in organic synthesis and asymmetric organocatalysis. Since 2009, his has been researcher in the Liver PET research group at the PET Centre. From 2013 to 2015, he also had a position of production manager at the section of Nuclear Medicine at Aarhus University Hospital. Along his career, he has visited the School of Chemistry, University of Nottingham in the UK and the Centre for Advanced Imaging, University of Queensland, St. Lucia, Brisbane in Australia. His research topic is the development of PET tracers to study liver functions. He is particularly interested in bile acids and their transport in liver and intestine, and he has developed the radiosynthesis for a series of carbon-11 labelled bile acid analogs including 11C-cholylsarcosine, which has proven useful for the quantification of conjugated bile acids transport in hepatocytes in healthy humans and in patients with cholestasis. He is an author of the book entitled Functional Molecular Imaging in Hepatology published by S Keiding and M Sørensen (Bentham eBook): Biliary secretion by K Frisch and AF Hofmann, pages 49 to 75. Open access

FRISCH KIM PET IMAGING.jpgDynamic PET/CT recording of bile acid tracer 11C-cholylsarcosine in a pig 1, 2, 15, and 38 min after intravenous bolus administration of tracer PubMed

  • J Hepatol. 2021;74:58-65. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis. Kjærgaard K, Frisch K, Sørensen M, Munk OL, Hofmann AF, Horsager J, Schacht AC, Erickson M, Shapiro D, Keiding S. PubMed
  • EJNMMI Radiopharm Chem. 2020;5:15. Intravenous and oral copper kinetics, biodistribution and dosimetry in healthy humans studied by [64Cu]copper PET/CT. Kjærgaard K, Sandahl TD, Frisch K, Vase KH, Keiding S, Vilstrup H, Ott P, Gormsen LC, Munk OL. PubMed
  • Appl Radiat Isot. 2019;152:172-179. Radiolabeling of protected tryptophan with [18F]fluoromethyl tosylate: Formation of [18F]fluoromethyl ester of tryptophan instead of 1-N-[18F]fluoromethyl tryptophan methylester. Venkatachalam TK, Stimson DHR, Frisch K, Pierens GK, Bhalla R, Reutens DC. PubMed
  • Nucl Med Biol. 2019;72-73:55-61. Human biodistribution, dosimetry, radiosynthesis and quality control of the bile acid PET tracer [N-methyl-11C]cholylsarcosine. Frisch K, Kjærgaard K, Horsager J, Schacht AC, Munk OL. PubMed
  • Nucl Med Biol. 2018;61:56-62. N-(4-[18F]fluorobenzyl)cholylglycine, a novel tracer for PET of enterohepatic circulation of bile acids: Radiosynthesis and proof-of-concept studies in rats. Frisch K, Stimson DHR, Venkatachalam T, Pierens GK, Keiding S, Reutens D, Bhalla R. PubMed
  • Am J Nucl Med Mol Imaging. 2018;8(2):73-85. Quantitative PET of liver functions. Keiding S, Sørensen M, Frisch K, Gormsen LC, Munk OL. PubMed
  • Physiol Biochem Zool. 2018;91:797-813. On the evolution of bile salts and the Farnesoid X receptor in vertebrates. Frisch K, Alstrup AKO. PubMedBiochim Biophys Acta. 2018;1864:1240-1244. Functional assessment of hepatobiliary secretion by 11C-cholylsarcosine positron emission tomography. Ørntoft N, Frisch K, Ott P, Keiding S, Sørensen M. PubMed
  • J Hepatol. 2017; 67(2):321-327. Hepatobiliary transport kinetics of the conjugated bile acid tracer 11C-CSar quantified in healthy humans and patients by Positron Emission Tomography (PET). Ørntoft NW, Munk OL, Frisch K, Ott P, Keiding S, Sørensen M. PubMed
  • J Nucl Med. 2016;57:961-6. Hepatobiliary secretion kinetics of conjugated bile acids measured in pigs by 11C-Cholylsarcosine PET. Sørensen M, Munk OL, Ørntoft NW, Frisch K, Andersen KJ, Mortensen FV, Alstrup AK, Ott P, Hofmann AF, Keiding S. PubMed
  • J Nucl Med. 2016;57:628-33. Radiosynthesis of N-11C-Methyl-Taurine-conjugated bile acids and biodistribution studies in pigs by PET/CT. Schacht AC, Sørensen M, Munk OL, Frisch K. PubMed
  • Nucl Med Biol. 2014;41:775. On fluoro-18 labeling of bile acids. Frisch K, Sørensen M. PubMed
  • J Nucl Med. 2014;55:590-4. The lumped constant for the galactose analog 2-18F-fluoro-2-deoxy-D-galactose is increased in patients with parenchymal liver disease. Mikkelsen KS, Sørensen M, Frisch K, Villadsen GE, Bibby BM, Keiding S. PubMed
  • J Hepatol. 2013;58:1119-24. Regional metabolic liver function measured in patients with cirrhosis by 2-[18F]fluoro-2-deoxy-D-galactose PET/CT. Sørensen M, Mikkelsen KS, Frisch K, Villadsen GE, Keiding S. PubMed
  • J Nucl Med. 2012;53:772-8. [N-methyl-11C]cholylsarcosine, a novel bile acid tracer for PET/CT of hepatic excretory function: radiosynthesis and proof-of-concept studies in pigs. Frisch K, Jakobsen S, Sørensen M, Munk OL, Alstrup AK, Ott P, Hofmann AF, Keiding S. PubMed
  • J Nucl Med. 2011;52:1566-72. Hepatic galactose metabolism quantified in humans using 2-18F-fluoro-2-deoxy-D-galactose PET/CT. Sørensen M, Mikkelsen KS, Frisch K, Bass L, Bibby BM, Keiding S. PubMed
  • Eur J Nucl Med Mol Imaging. 2011;38:1723-31. The potential use of 2-[18F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma. Sørensen M, Frisch K, Bender D, Keiding S. PubMed
  • Nucl Med Biol. 2011;38:477-83. Nucleophilic radiosynthesis of 2-[18F]fluoro-2-deoxy-D-galactose from Talose triflate and biodistribution in a porcine model. Frisch K, Bender D, Hansen SB, Keiding S, Sørensen M. PubMed

PubMed

Aarhus, Denmark

FRISCH KIM.jpg

Last update: August 2021